Propionic Acidemia News Today

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA ...

Operator: Good day, and thank you for standing by. Welcome to the Moderna Fourth Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.

William Blair initiated coverage on Moderna Inc (NASDAQ: MRNA) with a Market Perform rati

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacementTo date, mRNA-3927 has been generally well-tolerated at the doses administered, with encouraging early

Phase 1/2 Interim Data on Modernas mRNA-3927, an Investigational mRNA ...

Company in negotiations for new orders for fall of 2023 in U.S., Japan, and E.U., in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously... | May 4, 2023

Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA ...

After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to

MRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range from embracing AI to a 'bold campaign' of cancer vaccine studies.

Dear Editor: We want to thank each and everyone of you for all you have done for us. You are all so very kind and generous. It is completely overwhelming how much support we have gotten to help our baby girl. We are so fortunate to have so many people fighting for Quinnlyn through everything